Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc. is soliciting stockholder approval at a virtual special meeting on March 17, 2026 to authorize multiple capital and corporate-structure actions. Key items include approval to issue 3,685,815 shares upon exercise of December pre-funded warrants, approval of an equity line permitting up to $25 million or 19.99% (whichever is less) of newly issued shares, and approval to issue up to 109,978,918 shares upon exercise of February pre-funded warrants. The board also seeks authority to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-100 (aggregate not more than 1-for-250), to increase authorized common shares from 250,000,000 to 500,000,000, and to redomesticate the company to the Cayman Islands. Shares outstanding were 4,420,963 as of the Record Date.
CDT Equity Inc. director Farley Chele Chiavacci reported acquiring new equity-linked interests in connection with a share purchase deal. On February 19, 2026, the director agreed to transfer 18 shares of Sarborg Limited, valued at about $2,029,411, to CDT Equity.
As consideration, the director received 10,553 shares of CDT common stock and pre-funded warrants to purchase up to 1,940,804 CDT common shares at $1.04 per share. These pre-funded warrants cannot be exercised until CDT obtains requisite stockholder approval under Nasdaq Listing Rule 5635 and will remain exercisable until they are fully exercised.
CDT Equity Inc. Schedule 13G discloses that a group of related reporting persons collectively report 9.9% beneficial ownership of Common Stock as of 02/17/2026.
The filing shows 255,657 shares as the number with shared voting and dispositive power, Ascent directly holds 204,031 shares, and the ownership percentages are calculated using 2,303,490 shares outstanding and up to 51,626 shares issuable under a Directed Stock Purchase Agreement subject to a 9.99% ownership blocker.
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing holders. The shares relate to stock issued for consulting services, an equity line of credit with Ascent Partners Fund, and a sale-and-purchase agreement with Corvus Capital that includes pre-funded warrants.
This is a resale registration, so CDT will not receive proceeds from investors’ purchases under this prospectus. However, a separate equity line allows CDT, at its option, to sell up to $25 million of stock to Ascent over up to 36 months, subject to price and ownership limits.
Corvus, an entity controlled by CDT’s CEO, received CDT shares and 3,685,815 pre-funded warrants as $7,000,000 consideration for acquiring subsidiary CPL and its related litigation exposure. CDT highlights substantial funding needs, an accumulated deficit of $47.0 million as of September 30, 2025, a quarterly net loss of $7.1 million, potential Nasdaq listing risk, and the chance that these resales and any future issuances may significantly dilute existing stockholders and pressure the share price.
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing stockholders. The shares come from consulting fees, an equity line of credit with Ascent Partners Fund LLC, and a sale and purchase agreement with Corvus Capital Limited that included pre-funded warrants.
This is a secondary offering, so CDT will not sell any shares or receive proceeds from these resales. The company has also established a $25 million equity line facility with Ascent and sold subsidiary Conduit Pharmaceuticals Limited to Corvus as part of a $7 million settlement paid in stock and pre-funded warrants.
CDT Equity Inc. entered into a directed equity purchase agreement with an institutional investor, creating an equity line of credit facility of up to $25 million in common stock. The company can, at its option, direct the investor to buy shares over a period of up to 36 months, with each purchase priced at a discount to market based on recent volume-weighted average prices and subject to a $750,000 per-closing cap and trading-volume limits.
The investor is not required to buy shares that would push its beneficial ownership above 9.99% of CDT’s voting power, and generally will not buy if the stock trades below a floor price of $1.35, which resets every six months based on Nasdaq closing prices. As consideration, CDT agreed to issue 204,031 commitment shares of common stock. CDT plans to use any proceeds from share sales under this facility for working capital and general corporate purposes and has agreed to register the resale of both the purchased shares and the commitment shares.
CDT Equity Inc. filed its quarterly report for September 30, 2025. The company reported a net loss of $7.1 million for the quarter and $17.9 million for the nine months. Operating cash outflow was $10.9 million year‑to‑date, while cash and cash equivalents rose to $3.8 million from $0.6 million at year‑end, primarily from equity sales.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. The company plans to seek additional financing and noted its remaining at‑the‑market capacity of approximately $1.8 million was utilized after quarter‑end.
Stockholders’ equity improved to $4.3 million from a deficit, as additional paid‑in capital increased to $51.1 million. Convertible notes carried at fair value declined to $1.7 million from $5.9 million, reflecting conversions, repayments, and fair value changes; the company also recorded a $0.4 million waiver of accrued interest. CDT held $1.0 million of Bitcoin (8.65 BTC) as of quarter‑end. Shares outstanding were 1,276,574 as of September 30, 2025, and 1,629,402 as of November 13, 2025.
CDT Equity Inc. approved a 1-for-8 reverse stock split of its common stock, as described in an amendment to its certificate of incorporation filed in Delaware on October 8, 2025. At the effective time on October 10, 2025, every eight issued and outstanding shares of common stock will be combined into one share, while the par value and other terms of the stock remain unchanged.
The common stock is expected to begin trading on a reverse-split-adjusted basis on The Nasdaq Capital Market on October 13, 2025 under the ticker “CDT,” with a new CUSIP number 20678X403. No fractional shares will be issued; instead, stockholders entitled to a fraction will receive cash based on the split-adjusted closing price on October 10, 2025.
Amendment No. 3 to a Schedule 13D reports that Conduit Pharmaceuticals Inc. granted Dr. Andrew Regan 1,120,000 shares of common stock as director/officer compensation under the company’s Amended and Restated 2023 Stock Incentive Plan, valued at $0.6863 per share (closing Nasdaq price on September 18, 2025). The filing states 9,744,300 shares outstanding and discloses that Dr. Regan now beneficially owns 1,294,993 shares (approximately 13.3%) of the class, including shares held directly and through entities he controls. Corvus, Algo and Manoira ownership details are provided, and the Stock Incentive Plan is incorporated by reference as an exhibit.